Preclinical Evaluation of Safety and Biodistribution of Red Cell Microparticles: A Novel Hemostatic Agent

Ashish K. Rehni, Vibha Shukla, Hever Navarro Quero, Carlos Bidot, Conner R. Haase, Ensign Anise A. Crane, Shivam G. Patel, Sebastian Koch, Yeon S. Ahn, Wenche Jy, Kunjan R Dave

Research output: Contribution to journalArticle

Abstract

Background: Uncontrollable bleeding is a major cause of mortality and morbidity worldwide. Effective hemostatic agents are urgently needed. Red cell microparticles (RMPs) are a highly promising hemostatic agent. This study evaluated the safety profile of RMPs preliminary to clinical trial. Methods and Results: RMPs were prepared from type O+ human red blood cell by high-pressure extrusion. Male rats were treated with RMPs either a 1 × bolus, or 4 × or 20 × administered over 60 minutes. The vehicle-treated group was used as a control. Effects on physiological parameters were evaluated; namely, blood pressure, body and head temperature, hematocrit, and blood gases. We did not observe any adverse effects of RMPs on these physiological parameters. In addition, brain, heart, and lungs of rats treated with 4 × dose (bolus followed by infusion over 60 minutes) or vehicle were examined histologically for signs of thrombosis or other indications of toxicity. No thrombosis or indications of toxicity in brain, heart, or lungs were observed. Studies revealed that RMPs were distributed mainly in liver, spleen, and lymph nodes, and were potentially excreted through the kidneys. Conclusions: Our study indicates that RMP administration appears not to have any negative impact on the parameters studied and did not produce thrombosis in heart, brain, and lungs. However, more detailed long-term studies confirming the safety of RMP as a hemostatic agent are warranted.

Original languageEnglish (US)
JournalJournal of Cardiovascular Pharmacology and Therapeutics
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hemostatics
Safety
Thrombosis
Lung
Brain
Body Temperature
Hematocrit
Spleen
Erythrocytes
Gases
Lymph Nodes
Head
Clinical Trials
Hemorrhage
Blood Pressure
Morbidity
Kidney
Pressure
Mortality
Liver

Keywords

  • biodistribution
  • brain
  • heart
  • lungs
  • physiological parameters
  • thromboembolism

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Preclinical Evaluation of Safety and Biodistribution of Red Cell Microparticles : A Novel Hemostatic Agent. / Rehni, Ashish K.; Shukla, Vibha; Navarro Quero, Hever; Bidot, Carlos; Haase, Conner R.; Crane, Ensign Anise A.; Patel, Shivam G.; Koch, Sebastian; Ahn, Yeon S.; Jy, Wenche; Dave, Kunjan R.

In: Journal of Cardiovascular Pharmacology and Therapeutics, 01.01.2019.

Research output: Contribution to journalArticle

Rehni, Ashish K. ; Shukla, Vibha ; Navarro Quero, Hever ; Bidot, Carlos ; Haase, Conner R. ; Crane, Ensign Anise A. ; Patel, Shivam G. ; Koch, Sebastian ; Ahn, Yeon S. ; Jy, Wenche ; Dave, Kunjan R. / Preclinical Evaluation of Safety and Biodistribution of Red Cell Microparticles : A Novel Hemostatic Agent. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2019.
@article{ae2c13b4b3134d15b7f5c28cbe2e0c69,
title = "Preclinical Evaluation of Safety and Biodistribution of Red Cell Microparticles: A Novel Hemostatic Agent",
abstract = "Background: Uncontrollable bleeding is a major cause of mortality and morbidity worldwide. Effective hemostatic agents are urgently needed. Red cell microparticles (RMPs) are a highly promising hemostatic agent. This study evaluated the safety profile of RMPs preliminary to clinical trial. Methods and Results: RMPs were prepared from type O+ human red blood cell by high-pressure extrusion. Male rats were treated with RMPs either a 1 × bolus, or 4 × or 20 × administered over 60 minutes. The vehicle-treated group was used as a control. Effects on physiological parameters were evaluated; namely, blood pressure, body and head temperature, hematocrit, and blood gases. We did not observe any adverse effects of RMPs on these physiological parameters. In addition, brain, heart, and lungs of rats treated with 4 × dose (bolus followed by infusion over 60 minutes) or vehicle were examined histologically for signs of thrombosis or other indications of toxicity. No thrombosis or indications of toxicity in brain, heart, or lungs were observed. Studies revealed that RMPs were distributed mainly in liver, spleen, and lymph nodes, and were potentially excreted through the kidneys. Conclusions: Our study indicates that RMP administration appears not to have any negative impact on the parameters studied and did not produce thrombosis in heart, brain, and lungs. However, more detailed long-term studies confirming the safety of RMP as a hemostatic agent are warranted.",
keywords = "biodistribution, brain, heart, lungs, physiological parameters, thromboembolism",
author = "Rehni, {Ashish K.} and Vibha Shukla and {Navarro Quero}, Hever and Carlos Bidot and Haase, {Conner R.} and Crane, {Ensign Anise A.} and Patel, {Shivam G.} and Sebastian Koch and Ahn, {Yeon S.} and Wenche Jy and Dave, {Kunjan R}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1074248419838512",
language = "English (US)",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Preclinical Evaluation of Safety and Biodistribution of Red Cell Microparticles

T2 - A Novel Hemostatic Agent

AU - Rehni, Ashish K.

AU - Shukla, Vibha

AU - Navarro Quero, Hever

AU - Bidot, Carlos

AU - Haase, Conner R.

AU - Crane, Ensign Anise A.

AU - Patel, Shivam G.

AU - Koch, Sebastian

AU - Ahn, Yeon S.

AU - Jy, Wenche

AU - Dave, Kunjan R

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Uncontrollable bleeding is a major cause of mortality and morbidity worldwide. Effective hemostatic agents are urgently needed. Red cell microparticles (RMPs) are a highly promising hemostatic agent. This study evaluated the safety profile of RMPs preliminary to clinical trial. Methods and Results: RMPs were prepared from type O+ human red blood cell by high-pressure extrusion. Male rats were treated with RMPs either a 1 × bolus, or 4 × or 20 × administered over 60 minutes. The vehicle-treated group was used as a control. Effects on physiological parameters were evaluated; namely, blood pressure, body and head temperature, hematocrit, and blood gases. We did not observe any adverse effects of RMPs on these physiological parameters. In addition, brain, heart, and lungs of rats treated with 4 × dose (bolus followed by infusion over 60 minutes) or vehicle were examined histologically for signs of thrombosis or other indications of toxicity. No thrombosis or indications of toxicity in brain, heart, or lungs were observed. Studies revealed that RMPs were distributed mainly in liver, spleen, and lymph nodes, and were potentially excreted through the kidneys. Conclusions: Our study indicates that RMP administration appears not to have any negative impact on the parameters studied and did not produce thrombosis in heart, brain, and lungs. However, more detailed long-term studies confirming the safety of RMP as a hemostatic agent are warranted.

AB - Background: Uncontrollable bleeding is a major cause of mortality and morbidity worldwide. Effective hemostatic agents are urgently needed. Red cell microparticles (RMPs) are a highly promising hemostatic agent. This study evaluated the safety profile of RMPs preliminary to clinical trial. Methods and Results: RMPs were prepared from type O+ human red blood cell by high-pressure extrusion. Male rats were treated with RMPs either a 1 × bolus, or 4 × or 20 × administered over 60 minutes. The vehicle-treated group was used as a control. Effects on physiological parameters were evaluated; namely, blood pressure, body and head temperature, hematocrit, and blood gases. We did not observe any adverse effects of RMPs on these physiological parameters. In addition, brain, heart, and lungs of rats treated with 4 × dose (bolus followed by infusion over 60 minutes) or vehicle were examined histologically for signs of thrombosis or other indications of toxicity. No thrombosis or indications of toxicity in brain, heart, or lungs were observed. Studies revealed that RMPs were distributed mainly in liver, spleen, and lymph nodes, and were potentially excreted through the kidneys. Conclusions: Our study indicates that RMP administration appears not to have any negative impact on the parameters studied and did not produce thrombosis in heart, brain, and lungs. However, more detailed long-term studies confirming the safety of RMP as a hemostatic agent are warranted.

KW - biodistribution

KW - brain

KW - heart

KW - lungs

KW - physiological parameters

KW - thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85065255009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065255009&partnerID=8YFLogxK

U2 - 10.1177/1074248419838512

DO - 10.1177/1074248419838512

M3 - Article

C2 - 31035782

AN - SCOPUS:85065255009

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

ER -